Navigation Links
Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
Date:2/27/2012

HARBIN, China, Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ --  Weikang Bio-Technology Group Co., Inc. (WKBT.PK)("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company is expected to report its fiscal 2011 net profit of between $26 million to $28 million with EPS between $0.78 and $0.84 and revenue between $100 million and $102 millions.

"We are excited and confident about our results for 2011 and growth prospects beyond. The economy in China as we feel in general is slowing down, however we believe that the market for our high-quality therapeutics and health enhancement will continue to expand as China is expected to become the second largest pharmaceutical market by 2020," commented Mr. Yin Wang, Chairman and CEO of Weikang. "Moreover, our pipeline products on which our research team is focused address a large number of health problems and have a broad consumer appeal."

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit http://www.weikangbio.com.

Contact:
Yue Kang (Venus)
+86 451-8835-5530
+86 15846588061 
Email: weikangbio@yahoo.com

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.


'/>"/>
SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
2. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
3. Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance
4. Weikang Bio-Technology Announces Fiscal 2010 Financial Results
5. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
6. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
7. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
8. KJT Group Positions for Substantial Growth
9. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):